Sign In

Alex Dickinson

Life science/tech board member

Alex Dickinson is a seasoned executive and entrepreneur with extensive experience in healthcare, life sciences, and information technology. He currently serves as the Chair of Ryght, a California-based company he co-founded that applies generative AI to clinical trials.15

Professional Background

Current Roles::

  • Chair at Ryght4
  • Chairman of the Board at BC Platforms (appointed in July 2024)1
  • Board member of Chromacode, a cloud-based molecular diagnostics company1
  • Board member of Gencove, an NGS analytics software platform provider1

Previous Experience::

  • SVP Strategic Initiatives at Illumina (2010-2017), where he led the company's nation-scale precision medicine program and cloud computing efforts1
  • CEO and co-founder of Helixis, acquired by Illumina in 20101
  • CEO and co-founder of Luxtera (2001-2007), later acquired by Cisco Systems for $660M1

Education and Expertise

Alex Dickinson holds a PhD in Electrical Engineering from the University of Adelaide and an MBA from Columbia Business School in New York.1 He is known for his expertise in:

  • Precision medicine technology
  • Healthcare data management and analytics
  • Generative AI applications in healthcare
  • Cloud computing and bioinformatics
  • Mergers and acquisitions in the life sciences sector

Recent Appointments

In July 2024, Dickinson was appointed as the new Chairman of the Board at BC Platforms, a global leader in real-world data, healthcare data management, and analytics.1 His role at BC Platforms involves driving the company's strategic agenda and leveraging his experience in M&A and precision medicine to accelerate the company's growth as a global technology enabler for real-world data.1

Alex Dickinson is actively involved in the healthcare technology sector, particularly in companies leveraging AI and advanced analytics for clinical research and drug development. His LinkedIn profile (username: alexgdickinson) provides insights into his professional activities and thoughts on industry developments.23

Highlights

Sep 13 · linkedin

Great scoop by Jared Whitlock on the Illumina/GRAIL SEC investigation. As I noted yesterday, increasing numbers of people being questioned by the SEC and obviously Jared has had some good chats. Jared is an actual journalist and gets everything verified from at least two sources, so you can be sure this is the real deal:

"Endpoints News has learned that agency investigators have asked about whether forecasts by Grail’s management were too aggressive, and have asked about objections from inside the company by some employees who had reservations about the numbers." [more hints that the wall of silence is weakening, remember the GC just got his own counsel different to the board's? 🤔 ]

This also reflects with the rumors I've heard (eek maybe they came from me 🤪) that the SEC is also looking into GRAIL's publicly stated FDA timelines which may be in direct contradiction with what the FDA had actually told GRAIL confidentially (something to the effect of "you guys are crazy if you think this shitty NHS data is going to get you IVD this decade"):

"Last year, Grail reported $93.1 million in revenue, or about one-fifth of the conservative scenario in that same 2020 forecast. Grail had originally anticipated full FDA approval by now, a key milestone to set up insurance and government coverage for its pioneering cancer test."

👮👮👮

Sep 13 · linkedin

A big reason I just joined the board of Sphere Fluidics Limited is the huge demand I believe we'll see emerging for single cell platforms from the generative AI drug discovery boom centered around well-funded companies like Isomorphic Labs, CHARM Therapeutics and Xiara.

I was super excited to hear what Zach Weinberg (one of the Flatiron Health founders, sold for $2B to Roche, so no fool) said about AI and drug discovery on the Upstream podcast this week. It aligns perfectly with my Sphere thesis: AI drug discovery needs huge amounts of new data for learning, and huge capacity to try out new compounds to see if they work as advertised. Sphere will have a huge impact in both these areas.

Here's what Zach had to say -

"But I think like one FUNDAMENTAL DIFFERENT BETWEEN ATOMS AND BITS IS THE TRAINING DATA. The volume of training data that we have for pure digital applications like coding and automated email writing is like the history of written word of all time, and every video ever created. It's just an insane scale. But in biotech land where you're DEALING WITH ATOMS, you're have like one millionth - I don't actually know the exact number - but THE TRAINING DATA YOU HAVE TO TRAIN YOUR MODELS IS EXTREMELY LIMITED"

"And it's not just the LACK OF DATA that there is to train on. It's also that the coding and the email copilots are DETERMINISTIC in nature so you can validate the feedback loops in a very short manner. But in biotech, you have to MAKE THE MOLECULE . The feedback loops are long and it's not a yes or no. I mean, at the end of the day AI whether it's the new language models or the ML-driven stuff we had before, it's just making a prediction with varying levels of confidence."

"Now, obviously, the predictions are getting incrementally better, but you have to VALIDATE THE PREDICTION AND FEED IT BACK IN. That's really easy when the prediction is like, which emoji do I want to type to my friends? But when it's like, hey, you should MAKE THIS NEW MOLECULE or this new ligand or whatever, you have to physically go and manufacture it, and then you got to test it, and so THAT LOOP IS SLOW AND EXPENSIVE."

Related Questions

What are Alex Dickinson's main responsibilities at Ryght?
How did Alex Dickinson's experience at Illumina influence his role at Ryght?
What is the significance of generative AI in clinical trials at Ryght?
How has Alex Dickinson's leadership impacted the growth of Ryght?
What other companies has Alex Dickinson co-founded?
Alex Dickinson
Alex Dickinson, photo 1
Alex Dickinson, photo 2
Add to my network

Location

Laguna Beach, California, United States